Delving into the Latest Updates on TYK-01054 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

TYK 01054, TYK01054

Target

TEAD x YAP1

Action

inhibitors

Mechanism

TEAD inhibitors(TEA domain transcription factors inhibitors), YAP1 inhibitors(Yes1 associated transcriptional regulator inhibitors)

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Mesothelioma, MalignantAdvanced Malignant Solid NeoplasmAdvanced cancer

Inactive Indication-

Originator Organization

TYK Medicines, Inc.

Active Organization

TYK Medicines, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估TYK-01054 作为单药治疗晚期实体瘤参与者的安全性和耐受性，确定MTD、RDE、RP2D。评估 TYK-01054 对涉及或不涉及 Hippo 信号通路突变的晚期实体瘤的抗肿瘤活性。次要目的：评估 TYK-01054的药代动力学特征 (PK)，初步抗肿瘤活性。

[Translation]

Primary objective: To evaluate the safety and tolerability of TYK-01054 as monotherapy in participants with advanced solid tumors, and to determine MTD, RDE, and RP2D. To evaluate the antitumor activity of TYK-01054 against advanced solid tumors with or without Hippo signaling pathway mutations. Secondary objective: To evaluate the pharmacokinetic characteristics (PK) of TYK-01054 and its preliminary antitumor activity.

Start Date-

Sponsor / Collaborator

TYK Medicines, Inc.

100 Clinical Results associated with TYK-01054

Login to view more data

100 Translational Medicine associated with TYK-01054

Login to view more data

100 Patents (Medical) associated with TYK-01054

Login to view more data

100 Deals associated with TYK-01054

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mesothelioma, Malignant	Phase 2	China	TYK Medicines, Inc.	01 Jan 2026
Advanced Malignant Solid Neoplasm	Phase 2	China	TYK Medicines, Inc.	26 Dec 2025
Advanced cancer	IND Approval	United States	TYK Medicines, Inc.	11 Apr 2024